

Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY BIOPHARMA INC  
Form 4  
January 13, 2003

|  |  |  |
|--|--|--|
| <b>FORM 4</b>  | <b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b><br><b>Washington, D.C. 20549</b> | <b>OMB APPROVAL</b>  |
| o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.<br>See Instruction 1(b).<br>(Print or Type Responses)  | <b>STATEMENT OF</b><br><b>CHANGES IN BENEFICIAL OWNERSHIP</b>                            | OMB Number: 3235-0287<br>Expires: January 31, 2005<br>Estimated average burden hours per response .... 0.5 |
| Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,<br>Section 17(a) of the Public Utility Holding Company Act of 1935 or<br>Section 30(h) of the Investment Company Act of 1940 |  |  |

|  |   |   |
|--|---|---|
| 1. Name and Address of Reporting Person*<br><br>PISCOPIO      ANTHONY      D.<br><br>(Last)      (First)      (Middle)<br><br>3200 WALNUT STREET<br><br>(Street)<br><br>BOULDER      CO      80301<br><br>(City)      (State)      (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><br>ARRAY BIOPHARMA INC./ARRY<br><br>3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)<br><br>4. Statement for Month/Day/Year<br><br>1/10/03<br><br>5. If Amendment, Date of Original (Month/Day/Year) | 6. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br>_____ Director      _____ 10% Owner<br><br><input checked="" type="checkbox"/> Officer (give title below)      _____ Other (specify below)<br><br>VICE PRESIDENT, CHEMISTRY,<br>DIRECTOR OF PROCESS CHEMISTRY<br><br>7. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br>_____ Form filed by More than One Reporting Person |
|--|---|---|

**Table I Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| COMMON STOCK                    | 1/10/03                              | 1/10/03  | S                              | 1,000   | D   | \$4.90   |   |
| COMMON STOCK                    | 1/10/03                              | 1/10/03  | S                              | 1,500   | D   | \$4.98   |   |
| COMMON STOCK                    | 1/10/03                              | 1/10/03  | S                              | 1,500   | D   | \$5.00   |   |
| COMMON STOCK                    | 1/10/03                              | 1/10/03  | S                              | 500   | D   | \$5.08   |   |
|                                 | 1/10/03                              | 1/10/03  | S                              | 2,000   | D   | \$5.10   |   |

## Edgar Filing: ARRAY BIOPHARMA INC - Form 4

COMMON  
STOCK

|              |         |         |   |       |   |        |         |   |
|--------------|---------|---------|---|-------|---|--------|---------|---|
| COMMON STOCK | 1/10/03 | 1/10/03 | S | 2,500 | D | \$5.11 |         |   |
| COMMON STOCK | 1/10/03 | 1/10/03 | S | 500   | D | \$5.12 |         |   |
| COMMON STOCK | 1/10/03 | 1/10/03 | S | 2,761 | D | \$5.15 |         |   |
| COMMON STOCK | 1/10/03 | 1/10/03 | S | 500   | D | \$5.25 | 673,027 | D |

**Table II** Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

[illegible]

| 7. Title and Amount of Underlying Securities<br>(Instr. 3 and 4) | 8. Price of Derivative Security<br>(Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) | 10. Ownership Form of Derivative Securities: Direct (D) or Indirect (I)<br>(Instr. 4) | 11. Nature of Indirect Beneficial Ownership<br>(Instr. 4) |
|--|---|---|---|---|
|--|---|---|---|---|

## Edgar Filing: ARRAY BIOPHARMA INC - Form 4

(Instr. 4)

| Title | Amount or Number<br>of Shares |
|-------|-------------------------------|
|-------|-------------------------------|

**Explanation of Responses:**

/s/ Anthony D. Piscopio

January 13, 2003

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

<http://www.sec.gov/divisions/corpfin/forms/form4.htm>

*Last update: 09/05/2002*